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Respiratory muscle weakness is commonplace in 
critically ill patients, impairing the ability of those 
patients to breath, prolonging the need for ventilatory 
support, and increasing the likelihood of respiratory 
failure when that support is removed. Infections and 
endotoxemia reduce respiratory muscle strength, 
probably acting through several mechanisms – including 
increased oxidative stress, caspase activation leading to 
protein breakdown, and activation of the proteasome and 
calpain proteolytic systems resulting in protein loss. 
Supinski and colleagues report that the omega-3 fatty 
acid eicosapentaenoic acid (EPA) attenuates the loss in 
diaphragm speciﬁ  c force generation (that is, diaphragm 
strength) induced by bacterial endotoxin treatment in 
rats [1].
EPA is found in ﬁ   sh oils, along with its derivative 
docosahexaenoic acid. In the present study, pure EPA was 
administered orally on two occasions: the ﬁ  rst  at  the 
same time as endotoxin, and the second 24 hours later 
(G. Supinski, personal communication). Animals were 
sacriﬁ  ced 48  hours after the endotoxin administration. 
EPA was given at a dose of 1 g/kg body weight/day (that 
is, 2 g/kg). For a 250 g rat, the EPA dose equates to 0.25 g/
day (0.5 g in total). Th   is is similar to the amount of EPA 
that would be consumed by rats fed on a diet containing 
5 to 10% by weight as ﬁ  sh oil, as is commonly used in 
experimental studies. On the contrary, the amount of 
EPA provided here could not be translated directly to 
humans (70 g/day in a 70 kg individual) and is greatly in 
excess of amounts provided to patients receiving artiﬁ  cial 
nutrition either parenterally or enterally [2].
In this new study, endotoxin decreased diaphragm 
speciﬁ  c force generation by about 50%, while EPA almost 
totally prevented this reduction [1]. EPA might attenuate 
the loss of muscle strength through a variety of actions: 
EPA has been shown to act as a weak antioxidant [3], to 
inhibit proteasomes [4,5], to inhibit caspase activation [6] 
and to reduce inﬂ  ammation [7]. In the study of Supinksi 
and colleagues, EPA did not prevent the caspase activa-
tion or oxidative stress pathways in the diaphragm but it 
did reduce calpain activation [1], suggesting a speciﬁ  c 
eﬀ   ect on this proteolytic pathway. Supinski and 
colleagues thus report a highly novel eﬀ   ect of EPA 
(attenuation of endotoxin-induced loss of respiratory 
muscle strength) and a novel mecha  nism of action 
(reduced calpain activation) [1]. Th  e implication of this 
work is that administration of EPA may be able to 
decrease the respiratory, and perhaps other, muscle 
weakness that accompanies critical illness and sepsis.
Oral ﬁ   sh oil provided for a period of time prior to 
endotoxin administration has been shown to decrease 
post-endotoxin metabolic perturbations and inﬂ  amma-
tion, to improve heart and lung function, and to reduce 
mortality [8]. Th  ese studies provide EPA (and docosa-
hexaenoic acid) in advance of endotoxin treatment, which 
is not likely to be the best model for the clinical situation, 
and may favour an eﬀ   ect of EPA since it will be 
incorporated into cells and tissues in advance of the 
endotoxin stimulus. In Supinski and colleagues’ study, 
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© 2010 BioMed Central LtdEPA was administered at the same time as, and following, 
endotoxin administration, which is closer to the clinical 
situation [1]. In critically ill patients in the intensive care 
unit, parenteral ﬁ   sh oil improved lung function and 
decreased the length of hospital stay [9] while an enteral 
formula that included ﬁ  sh oil improved lung function 
[10], reduced requirement for ventilatory support [10,11], 
reduced risk of new organ failures [10-12], decreased the 
intensive care unit stay [10] and reduced mortality [11,12] 
in patients with acute respiratory distress syn  drome [10], 
with acute lung injury [11] or with sepsis [12].
Th  e eﬀ   ect on lung function has been linked to a 
reduction in inﬂ   ammation [9,10,13]. Th  is latest study, 
however, suggests that there may be an alternative 
mecha  nism: improved (or maintained) diaphragm 
function [1]. Th  e  ﬁ  ndings of Supinski and colleagues [1] 
indicate a rapid eﬀ  ect of EPA on the diaphragm that is 
consistent with the relatively short period of time 
required to improve lung function [9,10] and to reduce 
the need for ventilatory support [10,11] seen in these 
studies in critically ill patients. Th   ese latest observations 
are of signiﬁ   cance. It will be important, however, to 
identify whether EPA administration at a time after the 
initial insult (in this case, endotoxin) is also protective, 
since this would be most relevant to the clinical situation, 
to identify whether doses relevant to the human clinical 
situation are eﬀ   ective, to examine whether this eﬀ  ect 
occurs in patients receiving EPA, and to understand more 
about the mechanism that underpins this eﬀ  ect.
Abbreviations
EPA, eicosapentaenoic acid.
Competing interests
The author declares that he has no competing interests.
Published: 23 April 2010
References
1.  Supinski GS, Vanags J, Callahan LA: Eicosapentaenoic acid preserves 
diaphragm force generation following endotoxin administration. Crit Care 
2010, 14:R35.
2. Calder  PC:  Rationale and use of ω-3 fatty acids in artifi  cial nutrition. Proc 
Nutr Soc 2010, in press.
3.  Saito M, Kubo K: Relationship between tissue lipid peroxidation and 
peroxidizability index after alpha-linolenic, eicosapentaenoic, or 
docosahexaenoic acid intake in rats. Br J Nutr 2003, 89:19-28.
4.  Whitehouse AS, Tisdale MJ: Downregulation of ubiquitin-dependent 
proteolysis by eicosapentaenoic acid in acute starvation. Biochem Biophys 
Res Commun 2001, 285:598-602.
5.  Khal J, Tisdale MJ: Downregulation of muscle protein degradation in sepsis 
by eicosapentaenoic acid (EPA). Biochem Biophys Res Commun 2008, 
375:238-240.
6.  Magee P, Pearson S, Allen J: The omega-3 fatty acid, eicosapentaenoic acid 
(EPA), prevents the damaging eff  ects of tumour necrosis factor (TNF)-
alpha during murine skeletal muscle cell diff  erentiation. Lipids Health Dis 
2008, 7:24.
7. Calder  PC:  N-3 polyunsaturated fatty acids, infl  ammation, and 
infl  ammatory diseases. Am J Clin Nutr 2006, 83:1505S-1519S.
8. Calder  PC:  Use of fi  sh oil in parenteral nutrition: rationale and reality. Proc 
Nutr Soc 2006, 65:264-277.
9.  Barbosa VM, Miles EA, Calhau C, Lafuente E, Calder PC: Eff  ects of a fi  sh oil 
containing lipid emulsion on plasma phospholipid fatty acids, 
infl  ammatory markers, and clinical outcomes in septic patients: a 
randomized, controlled clinical trial. Crit Care 2010, 14:R5.
10.  Gadek JE, DeMichele SJ, Karlstad MD, Pacht ER, Donahoe M, Albertson TE, Van 
Hoozen C, Wennberg AK, Nelson JL, Noursalehi M: Eff  ect of enteral feeding 
with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in 
patients with acute respiratory distress syndrome. Enteral Nutrition in 
ARDS Study Group. Crit Care Med 1999, 27:1409-1420.
11.  Singer P, Theilla M, Fisher H, Gibstein L, Grozovski E, Cohen J: Benefi  t of an 
enteral diet enriched with eicosapentaenoic acid and gamma-linolenic 
acid in ventilated patients with acute lung injury. Crit Care Med 2006, 
34:1033-1038.
12.  Pontes-Arruda A, Aragão AM, Albuquerque JD: Eff  ects of enteral feeding 
with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in 
mechanically ventilated patients with severe sepsis and septic shock. Crit 
Care Med 2006, 34:2325-2333.
13.  Pacht ER, DeMichele SJ, Nelson JL, Hart J, Wennberg AK, Gadek JE: Enteral 
nutrition with eicosapentaenoic acid, gamma-linolenic acid, and 
antioxidants reduces alveolar infl  ammatory mediators and protein infl  ux 
in patients with acute respiratory distress syndrome. Crit Care Med 2003, 
31:491-500.
doi:10.1186/cc8951
Cite this article as: Calder PC: A novel eff  ect of eicosapentaenoic acid: 
improved diaphragm strength in endotoxemia. Critical Care 2010, 14:143.
Calder Critical Care 2010, 14:143 
http://ccforum.com/content/14/2/143
Page 2 of 2